The flavonoid Casticin has multiple mechanisms of tumor cytotoxicity action

Area of Science:

• Pharmacology
• Molecular Biology
• Cancer Research

Background:

• Flavonoids are plant-derived compounds with potential therapeutic properties.
• Casticin, a flavonoid from Achillea millefolium, has demonstrated anti-tumor effects.
• Understanding its precise mechanism is crucial for its development in cancer therapy.

Purpose of the Study:

• To elucidate the anti-tumor mechanism of the flavonoid Casticin.
• To investigate Casticin's effects on cell cycle regulation and apoptosis.
• To assess Casticin's potential as a cancer therapeutic agent.

Main Methods:

• Cell-based assays to study cell cycle progression.
• Western blotting to analyze protein expression (e.g., p21, Cdk1, cyclin A, Bcl-2).
• Transfection experiments to evaluate the role of Bcl-2 in Casticin resistance.

Main Results:

• Casticin induces cell growth arrest at the G2/M phase and triggers apoptotic cell death.
• As a tubulin-binding agent, Casticin upregulates p21, inhibiting Cdk1, and downregulates cyclin A.
• Casticin causes Bcl-2 depletion and sub-G1 accumulation; Bcl-2 overexpression confers resistance.
• Casticin is effective against Pgp-overexpressing and p53-mutant/null cancer cell lines.

Conclusions:

• Casticin's anti-tumor activity is mediated through cell cycle arrest at G2/M and induction of apoptosis.
• Its mechanism involves modulation of key cell cycle regulators and the Bcl-2 pathway.
• Casticin exhibits promising characteristics for cancer therapy, including efficacy in resistant cell lines.